Autonomix Medical Strengthens Global Intellectual Property Position with New Neural Sensing Patent Grant
Rhea-AI Summary
Autonomix Medical (NASDAQ: AMIX) announced the grant of Canadian Patent No. 3,158,197, "Endoscopic Sympathectomy Systems and Methods," strengthening its global intellectual property portfolio for nerve-targeted therapies and denervation applications. The company now holds 112 issued or pending patent applications worldwide, with coverage in the United States, Europe, Canada and other key jurisdictions.
The patent protects systems and methods for real-time nerve sensing, mapping, physiological monitoring and closed-loop neuromodulation using minimally invasive, sensor-enabled tools and implantable devices. These technologies are intended to enhance targeting of autonomic nerves involved in conditions such as hypertension, chronic heart failure, chronic renal failure and metabolic disorders, with expirations extending into the late 2030s.
Positive
- 112 issued or pending patent applications worldwide support multi-organ platform
- New Canadian patent expands protection for real-time nerve sensing and neuromodulation
- Patent coverage in US, Europe and Canada spans major commercial markets
- IP expirations into late 2030s provide long-duration protection for core platforms
Negative
- None.
News Explained
The holder-relevant disclosed change is IP-portfolio expansion, while any cash, ownership, or dilution effect is not established here.
On
In the release's description, the patent's closed-loop design means sensing physiological and electrophysiological responses before, during, and after treatment to help identify neural targets and assess treatment effects. The patent covers real-time monitoring, nerve mapping, feedback-guided neuromodulation, sensing and stimulating surgical tools, procedural-effectiveness evaluation, and implantable monitoring and modulation devices.
The supplied news record also lists a U.S. patent announcement dated
Sources and calculations
- Autonomix Medical patent grant release (2026-07-13)
- Autonomix Medical U.S. patent announcement (2026-05-19)
Market reaction: AMIX -12.48% on neural sensing patent grant
On the day this news was published, AMIX declined 12.48%, reflecting a significant negative market reaction. Argus tracked a peak move of +3.7% during that session. Argus tracked a trough of -39.9% from its starting point during tracking. Our momentum scanner triggered 26 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $509K from the company's valuation, bringing the market cap to $3.57M at that time. Trading volume was exceptionally heavy at 68.3x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 22 | platform update | Positive | +3.1% | Standalone neural sensing program with preclinical renal nerve activity evidence. |
| Jun 18 | reverse stock split | Negative | +4.3% | 1-for-21 reverse split to reduce outstanding shares while keeping authorization. |
| Jun 10 | investor update | Positive | -6.5% | CEO Corner segment on growing scientific and clinical recognition of platform. |
| Jun 04 | clinical data | Positive | +3.6% | Virtual segment discussing clinical data on visceral cancer pain treatment. |
| May 19 | patent grant | Positive | -10.0% | U.S. patent for transvascular monitoring and treatment with real-time feedback. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent Autonomix news, including patent wins and platform updates, has produced mixed share reactions, with several positive announcements met by negative price moves.
Key Terms
denervation medical
neuromodulation medical
microelectrode technical
electrophysiological medical
autonomic nervous system medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
IP portfolio reflects Autonomix’s neural sensing leadership in multi-billion-dollar denervation market
Technical highlights on newly issued patent include real-time nerve monitoring and diagnostic evaluation
THE WOODLANDS, TX, July 13, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that it has been granted Canadian Patent No. 3,158,197, titled "Endoscopic Sympathectomy Systems and Methods." The Company’s growing global intellectual property portfolio now includes 112 issued or pending patent applications worldwide with the newest patent further strengthening the Company’s intellectual property position across multiple nerve-targeted therapies and denervation applications.
The newly issued patent expands and reinforces Autonomix's intellectual property estate related to real-time nerve sensing, mapping, physiological monitoring, and feedback-guided neuromodulation technologies. The patented systems and methods are designed to enable more precise targeting of autonomic nerves associated with a variety of chronic disease states, including hypertension, chronic heart failure, chronic renal failure, metabolic disorders, and other conditions linked to autonomic nervous system dysfunction and renal sympathetic nerve hyperactivity.
Unlike conventional denervation approaches that rely primarily on anatomical landmarks, the patented technology incorporates sensing-enabled devices capable of detecting neural and physiological responses in real time. This closed-loop approach may enable physicians to locate neural targets more accurately, assess treatment effects during therapy delivery, and evaluate procedural success through objective physiological feedback.
Corresponding patents covering related inventions have previously been issued in the United States and Europe, reinforcing Autonomix's intellectual property position across major commercial markets.
"Securing this Canadian patent further strengthens our competitive position and expands the intellectual property foundation supporting our precision neuromodulation platform," said Brad Hauser, Chief Executive Officer of Autonomix. "We believe the ability to identify, monitor and modulate neural targets using real-time physiological feedback may represent a transformational advancement in nerve-targeted therapy. This patent not only reinforces our technological differentiation but also supports our vision of expanding the platform across multiple large clinical markets where improved treatment precision may lead to better patient outcomes."
The patent covers systems and methods designed to identify, monitor and modulate autonomic nerves using minimally invasive tools capable of sensing physiological and electrophysiological activity before, during and after treatment. Covered technologies include:
- Real-time monitoring of electrophysiological activity in the vicinity of organs and blood vessels;
- Nerve sensing and mapping technologies for identifying and characterizing autonomic neural targets;
- Closed-loop neuromodulation and denervation systems incorporating procedural feedback;
- Microelectrode- and microsensor-based surgical tools capable of sensing and stimulating tissue;
- Methods for evaluating the effectiveness of neuromodulation procedures through physiological monitoring; and
- Implantable devices for chronic monitoring and modulation of neural activity.
Autonomix has built a comprehensive intellectual property portfolio designed to provide broad, area-by-area protection across the body, encompassing core platforms for nerve sensing, nerve mapping, signal processing and controlled micro-ablation, along with application-specific innovations across multiple organ systems. With issued patents in the United States and key international jurisdictions, and expirations extending into the late 2030s, the portfolio is structured to support multi-organ platform scalability and expansion into diverse clinical indications.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.” Forward-looking statements in this press release include, but are not limited to, expectations regarding the scope, strength and competitive value of the Company's intellectual property portfolio, the potential effectiveness and clinical benefits of Autonomix's nerve-targeted treatments for pancreatic cancer pain and other conditions, the Company's planned U.S. clinical study, anticipated physician adoption, potential strategic partnerships, and reimbursement discussions.
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 27, 2026, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com
